Metronomic administration of chlorambucil for treatment of dogs with urinary bladder transitional cell carcinoma
Authors:
- Michael O. ChildressMCMichael O. Childress
- Jane C. StewartJSJane C. Stewart
- Tiffany N. LeachTLTiffany N. Leach
- Kean Ming TanKTKean Ming Tan
- Andrew H. AbboAAAndrew H. Abbo
- Amalia E. de GortariAGAmalia E. de Gortari
- Patty L. BonneyPBPatty L. Bonney
- Deborah W. KnappDKDeborah W. Knapp
- 1 June 2013
- journal article
- clinical trial
- Published by American Veterinary Medical Association (AVMA) in Journal of the American Veterinary Medical Association
- Vol. 242 (11) , 1534-1538
Abstract
Objective—To determine the antitumor effects and toxicoses of metronomic oral administration of a low dose of chlorambucil in dogs with transitional cell carcinoma (TCC). Design—Prospective clinical trial. Animals—31 client-owned dogs with TCC for which prior treatments had failed or owners had declined other treatments. Procedures—Chlorambucil (4 mg/m2, PO, q 24 h) was administered to dogs. Before and at scheduled times during treatment, evaluations of dogs included physical examination, CBC, serum biochemical analyses, urinalysis, thoracic and abdominal imaging including cystosonography for measurement of TCCs, and grading of toxicoses. Results—29 of 31 dogs had failed prior TCC treatment. Of the 30 dogs with available data, 1 (3%) had partial remission (≥ 50% reduction in tumor volume), 20 (67%) had stable disease (< 50% change in tumor volume), and 9 (30%) had progressive disease (≥ 50% increase in tumor volume or development of additional tumors); 1 dog was lost to follow-up. The median progression-free interval (time from the start of chlorambucil treatment to the day progressive disease was detected) for the dogs was 119 days (range, 7 to 728 days). The median survival time of dogs from the time of the start of chlorambucil treatment was 221 days (range, 7 to 747 days). Few toxicoses were detected; chlorambucil administration was discontinued because of toxicoses in only 1 dog. Conclusions and Clinical Relevance—Metronomic administration of chlorambucil was well tolerated, and 70% of dogs had partial remission or stable disease. Metronomic administration of chlorambucil may be a treatment option for dogs with TCC.Keywords
This publication has 24 references indexed in Scilit:
- Clinical Trial of Vinblastine in Dogs with Transitional Cell Carcinoma of the Urinary BladderJournal of Veterinary Internal Medicine, 2011
- Reappraising antiangiogenic therapy for breast cancerThe Breast, 2011
- Prospective trial of metronomic chlorambucil chemotherapy in dogs with naturally occurring cancerVeterinary and Comparative Oncology, 2011
- Doxycycline's Effect on Ocular Angiogenesis: An In Vivo AnalysisOphthalmology, 2010
- Metronomic Therapy with Cyclophosphamide and Piroxicam Effectively Delays Tumor Recurrence in Dogs with Incompletely Resected Soft Tissue SarcomasJournal of Veterinary Internal Medicine, 2008
- Evaluation of cisplatin administered with piroxicam in dogs with transitional cell carcinoma of the urinary bladderJournal of the American Veterinary Medical Association, 2007
- Continuous Low-Dose Oral Chemotherapy for Adjuvant Therapy of Splenic Hemangiosarcoma in DogsJournal of Veterinary Internal Medicine, 2007
- Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicityAnnals of Oncology, 2004
- Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levelsAnnals of Oncology, 2002
- Piroxicam Therapy in 34 Dogs With Transitional Cell Carcinoma of the Urinary BladderJournal of Veterinary Internal Medicine, 1994